Home » History

Our History

1837

Carlo Erba pharmacy and laboratory established

1936

Farmitalia established, acquires farming estate in Nerviano as veterinary outstation

1974

First ever anthracycline (Adriamycin) approved by FDA

1978

Farmitalia-Carlo Erba merge to form Farmitalia/Carlo Erba (FICE)

1993

FICE acquired by Kabi- Pharmacia To form Pharmacia

1995

Pharmacia merge with The Upjohn Company to become Pharmacia&Upjohn (PNU)

1997

PNU acquire SUGEN, becoming leaders of the kinase field

1999

Aromasin approved by FDA

2000

PNU merge with Searle/Monsanto to become Pharmacia

2003

Pharmacia Acquired by Pfzier

2004

Nerviano site spun off by Pfzier, acquired by CFIC and renamed as “Nerviano Medical Sciences, srl”, (NMS)

2010-2011

Encorafenib enabling IP licensed to Novartis.
Kinase platform agreement with Pfizer renegotiated, and a Region of Lombardy research foundation, “Fondazione Regionale per la Ricerca Biomedica (FRRB) takes over financial control of NMS

2012

Entrectinib, Phase I sponsored by NMS, enters FIH clinical testing, in 3 separate, rationally selected indications.

2018

Encorafenib approved by FDA in 2 independent indications.
Major stake in NMS is acquired by a Shanghai-based Chinese Venture Group, Hefei SARI V-Capital Management Co.

2019

Enrectinib approved by FDA in 2 independent indications

2019-2020-2021

NMS M801; P707; P912 and P807, all targeting different BIC/FIC mechanisms, programs start independent, mutinational, FIH clinical trials

People/Team
Mission, Vision and Values
Governance and Compliance
Collaboration and Partnership
Financials
MSCA Detrimode Project
Publication
People/Team
Mission, Vision and Values
Governance and Compliance
Collaboration and Partnership
Financials
MSCA Detrimode Project
Publication